Lazay boy, here are hight lights: 1). UCN2 phase II trial was completed last week, topline data will be reported later Feb or earlier March. 2). 32 patient VAMT2 phase II trial completed its enrollment, topline data will be reported before the end of March 3). VMAT2 program itself is a pipeline, preclinical data has shown it is was as effective as haloperidol is to treat Schizophrenia, Gorman was certainly more confident in his VMAT2 program future now than before because he must knew the ongoing trial site patient positive experiences; otherwise, he should only pump the VMAT2 program after the current trial is completed 4). Elagolix phase III trial will happen quickly - that is Gorman's original statement, no particular date was mentioned by him.
My prediction is THE TRIAN is going to leave the station before the end of March